Electromed adds John Erb and Greg Fluet to its Board of Directors

– USA, MN –  Electromed, Inc. (NYSE: ELMD), a leader in innovative airway clearance technologies, today announced that its Board of Directors has elected each of John L. Erb and Gregory J. Fluet to serve as directors of the company.

“We are pleased to have attracted two experienced executives from the medical device industry who will bring a wealth of relevant expertise,” said Steve Craney, Chairman of the Board. “These additions provide further strength to our board to further support Electromed’s growth opportunities.”

“John and Greg each bring an extensive background in strategy development, operations and finance and their addition speaks to Electromed’s commitment to penetrate the underserved market for non-cystic fibrosis bronchiectasis with our proven SmartVest Airway Clearance System,” said Kathleen Skarvan, President and CEO. “I believe their addition to our board will benefit our entire Electromed team to accelerate our profitable revenue growth goal.”

About John Erb

Mr. Erb has served as chief executive officer and president of CHF Solutions, Inc. (Nasdaq: CHFS) since 2015, and as a member of its board of directors and chairman since 2012. He has also served as chief executive officer and chairman of NeuroMedic, Inc., a private company he co-founded, since 2014. Previously, Mr. Erb served as chief executive officer, from 2007 to 2018, of NuAx, Inc., a private medical device company involved in developing new devices for the treatment of heart disease. Mr. Erb’s prior board experience includes serving as a director of SenoRx, Inc., then a Nasdaq-listed company, from 2001 until its acquisition in 2010; and as chairman of the board of Vascular Solutions, Inc., then a Nasdaq-listed company, until its acquisition in 2017. Mr. Erb currently serves as chairman of the board of Osprey Medical, Inc. (ASX: OSP) and as a director of MiroMatrix, a private biotechnology company, since 2017.

About Gregory Fluet

Mr. Fluet has served as a consultant with Ferring Pharmaceuticals, Inc. focused on microbiome commercialization and partnering since April 2018. He served as the chief business officer at Rebiotix, Inc., from April 2017 until its acquisition by Ferring Pharmaceuticals in April 2018. Prior to that, he started a strategic consulting practice working with various life science companies, including Rebiotix. Previously, he served as CEO of Urologix, Inc., then a public company, from 2012 to January 2016. He also served as its interim chief financial officer from August 2014 to May 2015 and as its executive vice president and COO from 2008 to 2012. From 2002 to 2008, he was employed as an associate at Sapient Capital Management, LLC, a healthcare-focused venture capital fund.

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System, to patients with compromised pulmonary function. The company is headquartered in New Prague, Minnesota and was founded in 1992.

For more information: https://smartvest.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.